TFF Pharmaceuticals Updates Progress of Human Clinical Trial with Tacrolimus Inhalation Powder

~ Company completes dosing of three cohorts with Tacrolimus Inhalation Powder for direct-to-lung delivery of a Thin Film Freezing dry-powder product for prevention of lung transplant rejection ~ Single ascending dose cohorts to date shown to be safe with no clinically significant drug-associated adverse events, while achieving substantial immunosuppressive blood levels

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here